Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 86

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 86
---
 or consultants will also be critical to our success. In addition, we rely
on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and preclinical studies
development and commercialization strategy. The loss of the services of our executive officers or other key employees and consultants
could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully
implement our business strategy.

Furthermore, replacing executive
officers and key employees or consultants may be difficult and may take an extended period of time, because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize
drug and diagnostics technology candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train,
retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel.

We also experience competition
for the hiring of scientific and clinical personnel from universities and research institutions. Our consultants and advisors may be employed
by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability
to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.

As of the date hereof, we
have 2 full-time employees, one of whom is the CEO and the other who is engaged in general and administrative functions and who is located
in Asia. In addition, we have engaged and may continue to engage independent contracted consultants and advisors to assist us with our
operations. As our development and commercialization plans and strategies develop, we will need to establish and maintain effective disclosure and financial controls and make changes in our corporate governance
practices. We will need to add a significant number of additional managerial, operational, sales, marketing, financial and other personnel
with the appropriate public company experience and technical knowledge and we may not successfully recruit and maintain such personnel.
Future growth will impose significant added responsibilities on members of management, including:

| ● | identifying, recruiting, integrating, maintaining and motivating additional employees;                                                                                                                                                                                         |
| ● | managing our internal development efforts effectively, including clinical, the FDA or other comparable regulatory authority review process for our drug and diagnostics technology candidates, while complying with our contractual obligations to contractors and others;